Cancer Treatment Reviews
Volume 37, Issue 1 , Pages 3-10 , February 2011

Hairy-cell leukemia variant: Recent view on diagnosis, biology and treatment

  • Tadeusz Robak

      Affiliations

    • Corresponding Author InformationTel.: +48 42 689 51 91; fax: +48 42 689 51 92.

Received 12 March 2010 ,Revised 20 May 2010 ,Accepted 25 May 2010.

References 

  1. Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980;4:547–559
  2. Cannon T, Mobarek D, Wegge J, Tabbara IA. Hairy cell leukemia: current concepts. Cancer Invest. 2008;26:860–865
  3. Foucar K, Catovsky D. Hairy cell leukemia. In: Jaffe S, Harris NL, Stein H, Wardman JW ED. WHO classification of haematopoietic and lymphoid tumors. Lyon: IARC Press, 2001. p. 138–41.
  4. Ott G, Balague-Ponz O, de Leval L, de Jong D, Hasserjian RP, Elenitoba-Johnson KS. Commentary on the WHO classification of tumors of lymphoid tissues: indolent B cell lymphomas. J Hematopathol. 2009;2:77–81
  5. Narat S, Gandla J, Dogan A, Mehta A. Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma. 2005;46:1229–1232
  6. Piris M, Foucar K, Mollejo M, Campo E, Falini B. Splenic B-cell lymphoma/leukemia unclassifiable. In: Swerdlow SH, Campo E, Harris NL et al., editors. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 191–2.
  7. Cessna MH, Hartung L, Tripp S, Perkins SL, Bahler DW. Hairy cell leukemia variant: fact or fiction. Am J Clin Pathol. 2005;123:132–138
  8. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia. 2001;15:184–186
  9. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003;16:41–56
  10. Ya-In C, Brandwein J, Pantalony D, Chang H. Hairy cell leukemia variant with features of intrasinusoidal bone marrow involvement. Arch Pathol Lab Med 2005;129:395–98.
  11. Zinzani PL, Lauria F, Buzzi M, Raspadori D, Gugliotta L, Bocchia M, et al. Hairy cell leukemia variant: a morphologic, immunologic and clinical study of 7 cases. Haematologica. 1990;75:54–57
  12. Sainati L, Matutes E, Mulligan S, de Oliveira MP, Rani S, Lampert IA, et al. A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood. 1990;76:157–162
  13. Razaq M, Perumandla S, Mankan N, et al. Hairy cell leukemia variant transforming into aggressive lymphoma with prostatic involvement in a patient with polycythemia vera. Leuk Lymphoma. 2006;47:754–757
  14. Hounieu H, Chittal SM, al Saati T, et al. Hairy cell leukemia. Diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DBA.44. Am J Clin Pathol. 1992;98:26–33
  15. Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20:1051–1063
  16. Wu ML, Kwaan HC, Goolsby CL. Atypical hairy cell leukemia. Arch Pathol Lab Med. 2000;124:1710–1713
  17. Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994;14(Suppl. 1):57–61
  18. Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 1993;82:1277–1287
  19. Del Giudice I, Matutes E, Morilla R, et al. . The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004;89:303–08.
  20. Yamaguchi M, Machii T, Shibayama H, et al. Immunophenotypic features and configuration of immunoglobulin genes in hairy cell leukemia-Japanese variant. Leukemia. 1996;10:1390–1394
  21. Quigley MM, Bethel KJ, Sharpe RW, Saven A. CD52 expression in hairy cell leukemia. Am J Hematol. 2003;74:227–230
  22. Brito-Babapulle V, Matutes E, Oscier D, Mould S, Catovsky D. Chromosome abnormalities in hairy cell leukaemia variant. Genes Chromosomes Cancer. 1994;10:197–202
  23. Vallianatou K, Brito-Babapulle V, Matutes E, Atkinson S, Catovsky D. p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant. Leuk Res 1999;23:1041–5.
  24. Machii T, Tokumine Y, Inoue R, Kitani T. Predominance of a distinct subtype of hairy cell leukemia in Japan. Leukemia. 1993;7:181–186
  25. Katayama I, Mochino T, Honma T, Fukuda M. Hairy cell leukemia: a comparative study of Japanese and non-Japanese patients. Semin Oncol 1984;11(4 Suppl. 2):486–92.
  26. Sasaki M, Aritaka N, Tsukune Y, Kawahara S, Masuda A, Tsutsui M, et al. Establishment of a hairy cell leukemia variant cell line, HCLv-07. Acta Haematol. 2009;121:63–66
  27. Traverse-Glehen A, Baseggio L, Callet-Bauchu E, et al. Hairy cell leukaemia-variant and splenic red pulp lymphoma: a single entity? Br J Haematol 2010 Mar 11. [Epub ahead of print] PubMed PMID: 20230408.
  28. Imamura T, Ohtsuka E, Ogata M, et al. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant. Int J Hematol. 2004;80:432–434
  29. Kitani T, Machii T, Inoue R, Kanakura Y. Hairy cell leukemia: a report of 10 cases in Japan and characterization of anti-hairy cell sera. Jpn J Clin Oncol. 1983;13:497–509
  30. Machii T, Yamaguchi M, Inoue R, et al. Polyclonal B-cell lymphocytosis with features resembling hairy cell leukemia-Japanese variant. Blood. 1997;89:2008–2014
  31. Matutes E, Oscier D, Montalban C, Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008;22:487–95.
  32. Dong HY, Weisberger J, Liu Z, Tugulea S. Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders: hairy cell leukemia and its mimics. Am J Clin Pathol. 2009;131:586–595
  33. Sun T, Dittmar K, Koduru P, Susin M, Teichberg S, Brody J. Relationship between hairy cell leukemia variant and splenic lymphoma with villous lymphocytes: presentation of a new concept. Am J Hematol 1996;51:282–8.
  34. Arcaini L, Paulli M. Splenic marginal zone lymphoma: a hydra with many heads?. Haematologica. 2010;95:534–537
  35. Kent SA, Variakojis D, Peterson LC. Comparative study of marginal zone lymphoma involving bone marrow. Am J Clin Pathol. 2002;117:698–708
  36. Matsuda F, Ishii K, Bourvagnet P, et al. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J Exp Med. 1998;188:2151–2162
  37. Martín-Jiménez P, García-Sanz R, González D, et al. Molecular characterization of complete and incomplete immunoglobulin heavy chain gene rearrangements in hairy cell leukemia. Clin Lymphoma Myeloma. 2007;7:573–579
  38. Hockley SL, Giannouli S, Morilla A, et al. Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol 2009 October 22. [Epub ahead of print].
  39. Arons E, Sunshine J, Suntum T, Kreitman RJ. Somatic hypermutation and VH gene usage in hairy cell leukaemia. Br J Haematol. 2006;133:504–512
  40. Arons E, Margulies I, Sorbara L, et al. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res. 2006;12:2804–2811
  41. Maloum K, Magnac C, Azgui Z, et al. VH gene expression in hairy cell leukaemia. Br J Haematol. 1998;101:171–178
  42. Thorsélius M, Walsh SH, Thunberg U, Hagberg H, Sundström C, Rosenquist R. Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia. Leuk Res. 2005;29:153–158
  43. Tierens A, Delabie J, Malecka A, et al. Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. Am J Pathol. 2003;162:681–689
  44. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854
  45. Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood. 2009;114:4696–4702
  46. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114:4687–4695
  47. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev. 2006;32:365–376
  48. Robak T, Błasińska-Morawiec M, Błoński J, et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999;62:49–56.
  49. Dunphy CH, Petruska PJ. Atypical prolymphocytic variant of hairy-cell leukemia: case report and review of the literature. Am J Hematol. 1996;53:121–125
  50. Mercieca J, Matutes E, Emmett E, Coles H, Catovsky D. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol. 1996;93:409–411
  51. Dunn P, Shih LY, Ho YS, Tien HF. Hairy cell leukemia variant. Acta Haematol. 1995;94:105–108
  52. Sgarabotto D, Vianello F, Radossi P, et al. Remission in hairy cell leukemia-variant following splenic radiotherapy alone. Leuk Lymphoma. 1997;26:395–398
  53. Sasaki M, Sugimoto K, Mori T, Karasawa K, Oshimi K. Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Acta Haematol. 2008;119:45–48
  54. Polliack A. Hairy cell leukemia and allied chronic lymphoid leukemias: current knowledge and new therapeutic options. Leuk Lymphoma. 1997;26(Suppl. 1):41–51
  55. Ahmed S, Rai KR. Interferon in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol. 2003;16:69–81
  56. Dadmarz R, Evans T, Secher D, Marshall N, Cawley JC. Hairy cell possess more interferon receptors than other lymphoid cell types. Leukemia. 1987;1:357–361
  57. Blasińska-Morawiec M, Robak T, Krykowski E, Hellmann A, Urbańska-Ryś H. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine – a report of three cases. Leuk Lymphoma. 1997;25:381–385
  58. Tetreault SA, Robbins BA, Saven A. Treatment of hairy cell leukemia-variant with cladribine. Leuk Lymphoma. 1999;35:347–354
  59. Palomera L, Domingo JM, Sola C, Azaceta G, Calvo MT, Gutierrez M. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica. 2002;87:107–108
  60. Machii T, Chou T, Suzuki M, et al. Cladribine Study Group Phase II clinical study of cladribine in the treatment of hairy cell leukemia. Int J Hematol. 2005;82:230–235
  61. Miyazaki M, Taguchi A, Sakuragi S, Mitani N, Matsuda K, Shinohara K. Hairy cell leukemia, Japanese variant, successfully treated with cladribine. Rinsho Ketsueki. 2004;45:405–407
  62. Lefrère F, Hermine O, François S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma. 2000;40:113–117
  63. Grever MR, Doan CA, Kraut EH. Pentostatin in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol. 2003;16:91–99
  64. Catovsky D, Matutes E, Talavera JG, et al. Long-term results with 2′-deoxycoformycin in hairy cell leukemia. Leuk Lymphoma. 1994;14(Suppl. 1):108–113
  65. Dunphy CH, Petrusk PJ. Atypical prolymphocytic variant of hairy cell leukemia: case report and review of the literature. Am J Hematol. 1996;53:121–125
  66. Sanati L, Matutes E, Mulligan S, et al. Variant form of hairy cell leukemia resistant to interferon-α: clinical and phenotypic characteristics of 17 patients. Blood. 1990;76:157–162
  67. Ng JP, Nolan B, Chan-Lam D, Coup AJ, McKenna D. Successful treatment of aplastic variant of hairy-cell leukaemia with deoxycoformycin. Hematology. 2002;7:259–262
  68. Nagai T, Izumi T, Noborio K, et al. Successful treatment of hairy cell leukemia prolymphocytic variant with 2′-deoxycoformycin. Rinsho Ketsueki. 2002;43:583–585
  69. Ribeiro P, Bouaffia F, Peaud PY, et al. Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer. 1999;85:65–71
  70. Kantarjian HM, Schachner J, Keating MJ. Fludarabine therapy in hairy cell leukemia. Cancer. 1991;67:1291–1293
  71. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003;102:810–813
  72. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol. 2001;115:609–611
  73. Thomas DA, O’Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102:3906–3911
  74. Angelopoulou MK, Pangalis GA, et al. Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab. Leuk Lymphoma 2008;49:1817–20.
  75. Fietz T, Rieger K, Schmittel A, Thiel E, Knauf W. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol J. 2004;5:451–452
  76. Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma. 2004;45:205–219
  77. Hadzi-Pecova L, Stojanovik A, Petrusevska G, Panovska I. Rituximab in the treatment of the variant of hairy cell leukaemia: a case report. Prilozi 2008;29:355–60.
  78. Makita M, Nakamura K, Kono A. Successful rituximab treatment in a patient with refractory hairy cell leukemia-Japanese variant and suffering from acute respiratory distress. Rinsho Ketsueki. 2005;46:1196–1201
  79. Quach H, Januszewicz H, Westerman D. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica 2005;90 Suppl.:EO CR26.
  80. Imamura T, Ohtsuka E, Ogata M, et al. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant. Int J Hematol 2004;80:432–34.
  81. Robak T. Improving FCR immunochemotherapy in CLL. Blood. 2010;115:437–438
  82. Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs. 2009;69:2415–2449
  83. Robak T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2008;8:1033–1051
  84. Quigley MM, Bethel KJ, Sharpe RW, Saven A. CD52 expression in hairy cell leukemia. Am J Hematol. 2003;74:227–230
  85. Telek B, Batár P, Udvardy M. Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant. Orv Hetil. 2007;148:1805–1807
  86. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241–247
  87. Kreitman RJ, Pastan I. Immunobiological treatments of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003;16:117–133
  88. Kreitman RJ, Tallman MS, Coutre S, et al. Phase I dose-escalation study of CAT-8015 (HA22), a CD22-specific targeted immunotoxin, in relapsed or refractory hairy cell leukemia. Blood (ASH Annual Meeting Abstracts) 2009;114:888.
  89. Goldaniga M, Guffanti A, Gianelli U, et al. Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab. Haematologica 2004;89:ECR41, e138–9.
  90. Busemann C, Schüler F, Krüger W, et al. Late extramedullary relapse after allogeneic transplantation in a case of variant hairy cell leukaemia. Bone Marrow Transplant 2009 Oct 12. [Epub ahead of print].
  91. Knight C,Lee EJ. Rituxan is an effective agent in variant hairy cell leukemia. Blood 2002;100:311b (Abstract 4786).

☆ Presented in part at Conference ‘Treatment of Hairy-Cell Leukemia in its Second Half-Century’ April 26–27, 2010, National Institutes of Health, Bethesda, MD, USA.

PII: S0305-7372(10)00102-7

doi: 10.1016/j.ctrv.2010.05.003

Cancer Treatment Reviews
Volume 37, Issue 1 , Pages 3-10 , February 2011

Article Tools

* Image Usage & Resolution